跳至主要内容
临床试验/NCT04260789
NCT04260789Unknown不适用

Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection

ExThera Medical Europe BV25 个研究点 分布在 9 个国家目标入组 232 人开始时间: 2020年8月19日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
232
试验地点
25
主要终点
Reduction of pathogens load

研究概览

简要总结

Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the reduction of pathogen load from the blood in septic patients with suspected, life-threatening bloodstream infection

详细描述

With the lack of effective antibiotics for many bloodstream infections, and limited new anti-infectives in development, there is a significant unmet need for new approaches that can help treat drug-resistant infections, especially in patients at high risk. There is an unmet need for a safe and broad-spectrum hemoperfusion therapy that can quickly reduce bacterial load and shorten the duration of bacteremia, preferably without the need to first identifying the type of bacteria present in the blood. There is an emerging need to increase the efficacy of effective antibiotics, e.g., by using hemadsorption as adjunctive therapy, to by quickly reducing bacterial load while scavenging toxins released from bacteria. Finally, there is a medical growing need for an alternative therapy when no effective antibiotic is available.

Seraph 100 Microbind Affinity Blood Filter is used to reduce pathogen load during bloodstream infection. Bacteremia or bloodstream infection, also called BSI, occurs when a bacterial infection elsewhere in the body enters the bloodstream. This clinical condition can quickly become life-threatening and progress to sepsis. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection (Singer et al., 2016).When sepsis occurs with extremely low blood pressure, it's called septic shock. Septic shock is fatal in many cases.

Sepsis can be triggered by many types of bacteremia although the exact source of the infection often cannot be determined. Some of the most common infections that lead to BSI are lung infections (i.e. pneumonia) and infections in the abdominal area. Patients who are already in the hospital for something else, such as a surgery, are at a higher risk of developing BSI. These infections are even more dangerous when the bacteria are already resistant to antibiotics. The National Institutes of Health (NIH) estimates that over 1 million Americans get sepsis each year. Between 28 and 50 percent of these patients may die from the condition.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with sepsis and suspected bloodstream infection
  • Be ≥ 18 years old and ≤ 90 years old
  • Adults receiving IV antibiotic therapy
  • Increase of at least two points of the Sequential Organ Failure Assessment (SOFA) score
  • Subjects that presents Procalcitonin (PCT) levels > 0,5 ng/mL

排除标准

  • Subject is currently participating in another clinical investigation
  • Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
  • Presence of comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
  • The first dose of the current antibiotic therapy was > 24 h before screening
  • Have Child-Pugh Class C cirrhosis
  • Have platelet count < 30.000/uL
  • Contraindications for heparin sodium for injection
  • Subjects demonstrating any contraindication for this treatment as described in the IFU

结局指标

主要结局

Reduction of pathogens load

时间窗: 4,5 hours +/- 30 min

Reduction of pathogens load from the bloodstream during treatment

次要结局

  • Change of Intensive Care Unit (ICU) complications(Daily during ICU stay or at least day 1, day 2, day 7)
  • Persistence/Recurrence of bacteremia(Day 1, day 2, day 7)
  • Persistence/Recurrence of sepsis(Daily during ICU stay or at least day 1, day 2, day 7)
  • Organ dysfunction-free days(Daily during ICU stay or at least day 1, day 2, day 7)
  • All-cause mortality(90 days)
  • Length of stay (LOS) at ICU and hospital ward(During ICU and hospital ward stay or at least day 1, day 2, day 7)
  • Ventilator-free days (VFDs)(Daily during ICU stay or at least day 1, day 2, day 7)

研究者

发起方
ExThera Medical Europe BV
申办方类型
Industry
责任方
Sponsor

研究点 (25)

Loading locations...

相似试验